Skip to main content
. 2017 Feb 10;312(5):L760–L771. doi: 10.1152/ajplung.00484.2016

Fig. 5.

Fig. 5.

Bone morphogenetic protein receptor type II (BMPRII) vs. transforming growth factor-β (TGF-β1) receptor I (TGFR1) signaling during ALI. A: TGF-β1 was measured in cell-free BALF after 1 or 4 days of LPS challenge in WT mice. B: representative Western blot showing BMPRII, TGFRI, P-SMAD1/5/8/9, P-SMAD2/3, and β-actin expression levels in lung lysates from WT mice exposed to saline or LPS (up to 4 days). C, D, and E: densitometry analysis of BMPRII short (SF) and long form (LF), P-SMADs, and TGFRI expression. F: BMPRII and TGFRI expression in HPAECs treated with IL-6/IL-6R or 3-morpholinosydnonimine (SIN-1) (96 h) compared with control. *P < 0.01, **P < 0.001, and ***P < 0.0001 by one-way ANOVA followed by post hoc Newman-Keuls test (n = 3–4 mice per experimental group).